Indofarma Tbk.

inaf

Overview

INAF Overview

PT Indofarma Tbk is an Indonesia-based company, which is engaged in the healthcare industry. The Company's business segment based on the products consists of the drug business segment and other medical equipment segment. The medical equipment segment consists of diagnostic and medical equipment. Its business segment based on geographical distribution area covers five regions consisting of Sumatra, Java, Kalimantan, Sulawesi and Bali, West Nusa Tenggara, and East Indonesia. Its products and services include generic drugs, over-the-counter and food, medical devices, non-medical devices and household health products. The Company carries out business activities to produce either alone or under cooperation for finished drug products, such as essential medicines, generic medicines with logos, generic medicines with trade names, traditional medicines, medical equipment, diagnostics, as well as food products, both related to health maintenance and improvement as well as health restoration.

24681012ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: INAF

Watchlist
Market Cap.
IDR 774.82Billion

~$49.31M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

INAF Valuation Metrics

250

IDR

Closing Price on 2024-04-05

Price to Equity

-1.77

P/E

At -1.77x P/E TTM, INAF.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

-7.36

P/B

At -7.36x P/B TTM, INAF.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

1.13

P/S

At 1.13x P/S TTM, INAF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Indofarma Tbk. based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Indofarma Tbk. relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
-3.05x
Price/Forward Earnings
-
Enterprise Value/Revenue
1.90x
Enterprise Value/EBITDA
-2.74x
PEG Ratio
-0.08x

Analyst Ratings

No analyst ratings available yet.

Valuation Recap of INAF stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of -1.77x is below the ID market average of 8.22x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (8.87x). ●●
Max 3
High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of -7.36x is below the peers average of 1.29x in the Pharmaceuticals & Health Care Research sector. In fact, less than 25% of its peers trade at a lower P/B ratio than INAF.●●●
Max 3
Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 1.13x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of INAF's valuation relative to its current sales and future earnings growth.
Max 2
Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. INAF's P/CF ratio of -3.05x is considered healthy by analysts.●●
Max 2
Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. INAF's EV/R ratio of 1.90x is considered fairly underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.40x.
Max 3

Peers

INAF Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk68.46T27.18T 30.31T 2.96T 23.123.31
MIKAPT Mitra Keluarga Karyasehat Tbk.39.22T7.11T 4.13T 0.95T 41.297.01
SILOPT Siloam International Hospitals Tbk.32.40T10.75T 10.83T 1.11T 29.294.28
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.62T 2.35T -0.05T -433.0911.10
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk20.25T3.75T 3.61T 0.97T 20.865.94
HEALPT Medikaloka Hermina Tbk.19.03T8.52T 5.54T 0.48T 39.485.15
PRAYPT Famon Awal Bros Sedaya Tbk9.42T4.42T 1.70T 0.18T 53.643.42
TSPCTempo Scan Pacific Tbk9.09T11.31T 12.93T 1.41T 6.431.18
SOHOPT Soho Global Health Tbk6.24T4.67T 7.91T 0.34T 18.422.45
KAEFKimia Farma Tbk.5.04T8.99T 10.19T -0.17T -30.26
Competitiveness Recap of INAF stock
WeightNotesScore
High
At a market cap of IDR 774.82 billion, INAF.JK ranks 10 in Market Cap out of 10 companies in the Healthcare sector.
Max 2
High
At a PE of -1.77, INAF.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -20.23 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (53.64) in the Healthcare sector.
Max 2
Medium
At a PE of -1.77, INAF.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 8.87). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.
Max 2
Medium
At a revenue of IDR 0.68 trillion, INAF.JK ranks 10 in Revenue out of 10 companies in the Healthcare sector.
Max 2
Medium
At a profit of -IDR 0.44 trillion, INAF.JK ranks 10 in Profit out of 10 companies in the Healthcare sector.
Max 2

Future

Future Growth of INAF

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are shrinking at a projected rate of -1.18% against the IDX average of +12.0%.

Pharmaceuticals & Health Care Research sector overview
No data is available for INAF at the moment.
Future growth prospect of INAF
WeightNotesScore
High
INAF's projected growth rate of -1.18% is below the ID market average of 11.98%.●●●
Max 3
High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 11.14% in 2024. This number is higher than the previous year 2023's growth rate of 2.48%. This bodes well for INAF's revenue growth prospects in the next 2 years. ●●
Max 3
Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 2.56% in 2024. This number is higher than the previous year 2023's EPS growth of -8.71%. false
Max 3
Medium
INAF and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2024. Specifically, earnings are projected to increase by 16.30% in 2024 while revenue growth is projected to increase by 17.10%. These macroeconomic trends will likely be a tailwind for INAF's earnings growth prospects in the next 2 years. ●●
Max 3
Loading...
Loading...

Management

Executive Management

President Director

Agus Heru Darjono15.2 years
Ariesta Krisnawan
Director
Jejen Nugraha
Director
Kamelia Faisal
Director
NamePositionShares%
No data is available for INAF at the moment.
Expressed in millions IDR, unless otherwise stated

Ownership

INAF Ownership

Others
11.99%
Insiders
88.01%
Institutions
0%
NameNumber of SharesOwnership (%)Value
Pt Bio Farma (Persero)2,499,999,99980.66625.00B
Public371,733,65111.9992.93B
Pt Asabri (Persero) - Dapen Tni227,533,8507.3456.88B
No data is available for INAF at the moment.